Summary
Telmisartan, a highly selective angiotensin-II-receptor antagonist, used for the treatment of hypertension, acts as a partial agonist of the PPAR-γ (peroxisome proliferator-activated receptor-γ) rezeptor, which is involved in the regulation of glucose and lipid metabolism. In the present study the effect of Telmisartan on hypertension, parameters of glucose and lipid metabolism was investigated in 670 patients with the metabolic syndrome. There was a significant (p < 0,05) improvement regarding all parameters involved in the diagnosis of the metabolic syndrome, namely hypertension (systolic: 161,7 ± 16,3 vs. 136,7 ± 11,7 mmHg, diastolic: 93,3 ± 10,1 vs. 80,7 ± 10,5 mmHg), fasting blood glucose (133,2 ± 44,1 vs. 116,0 ± 31,5 mg/dl), triglycerides (227,2 ± 170,1 vs. 187,8 ± 94,8 mg/dl), HDL-cholesterin (women: 48,9 ± 13,1 vs. 51,8 ± 12,9 mg/dl) and abdominal circumference (women: 101,2 ± 12,4 vs. 99,3 ± 12,9 mg/dl, men: 111,9 ± 14,7 vs. 109,5 ± 14,4 mg/dl). The number of patients diagnosed with the metabolic syndrome was significantly reduced over the 3 months study duration (38%). The medication was well tolerated and adverse effects were minimal. Thus, Telmisartan can be regarded as an appropriate medication for the therapy of hypertension in patients with the metabolic syndrome with possible additive effects on parameters of glucose and lipid metabolism.
Zusammenfassung
Telmisartan, ein hochselektiver Angiotensin-II-Rezeptorblocker für die Behandlung von Bluthochdruck, fungiert als partieller Agonist des PPAR-γ (peroxisome proliferator-activated receptor-γ) Rezeptors, welcher in die Regulation des Lipid- und Glukosestoffwechsels involviert ist. In der vorliegenden Anwendungsbeobachtung wurde der Einfluss von Telmisartan und Telmisartan/Hydrochlorothiazid auf Blutdruck, Blutzuckerund Lipidparameter bei insgesamt 670 Patienten mit metabolischem Syndrom untersucht. Eine Verbesserung (p < 0,05) zeigte sich bei allen Parametern, die als Diagnosekriterien für das metabolische Syndrom gelten, nämlich Blutdruck (systolisch: 161,7 ± 16,3 vs. 136,7 ± 11,7 mmHg, diastolisch: 93,3 ± 10,1 vs. 80,7 ± 10,5 mmHg), Nüchternblutzucker (133,2 ± 44,1 vs. 116,0 ± 31,5 mg/dl), Triglyzeride (227,2 ± 170,1 vs. 187,8 ± 94,8 mg/dl), HDL-Cholesterin (Frauen: 48,9 ± 13,1 vs. 51,8 ± 12,9 mg/dl), und Bauchumfang (Frauen: 101,2 ± 12,4 vs. 99,3 ± 12,9 mg/dl, Männer: 111,9 ± 14,7 vs. 109,5 ± 14,4 mg/dl). Die Häufigkeit der Diagnose eines metabolischen Syndroms konnte in drei Monaten signifikant um 38 % gesenkt werden. Telmisartan wurde insgesamt sehr gut vertragen und es traten kaum Nebenwirkungen auf. Diese unter Praxisbedingungen erhobenen Daten belegen die günstige Wirkung von Telmisartan auf den Blutdruck sowie Parameter des Glukose- und Lipidstoffwechsels bei hypertensiven Patienten mit metabolischem Syndrom.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literatur
European Society of Hypertension-European Society of Cardiology (2003) Guidelines for the management of arterial hypertension. J Hypertens 21: 1011–1053
Veterans Administration Cooperative Study Group on antihypertensive agents (1970) Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 213: 1143–1152
Chrysant SG, Chrysant GS, Desai A (2005) Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. J Hum Hypertens 19: 173–183
Bakris GL, Mensah GA (2002) Pathogenesis and clinical physiology of hypertension. Cardiol Clin 20: 195–206
Unger T (2003) Blood pressure lowering and renin-angiotensin system blockade. J Hypertens (Suppl 21): S3–S7
Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022–2031
Sharpe M, Jarvis B, Goa KL (2001) Telmisartan: a review of its use in hypertension. Drugs 61: 1501–1529
Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension 43: 993–1002
Yamagishi S, Takeuchi M (2005) Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses 64: 476–478
Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, Fujikura J, Chusho H, Ebihara K, Hayashi T, Hosoda K, Nakao K (2004) An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 576: 492–497
Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM (2005) Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 4: 6
IDF consensus worldwide definition of the metabolicsyndrome (2005) (publiziert 14. April http://www.idf.org/webdata/docs/Metabolic_syndrome_definition.pdf)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tripp, B., Ludvik, B. Antihypertensive und metabolische Effekte von Telmisartan bei Patienten mit metabolischem Syndrom in der Praxis – eine Anwendungsbeobachtung. Wien Med Wochenschr 157, 223–227 (2007). https://doi.org/10.1007/s10354-007-0407-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10354-007-0407-9